/ Welcome to Scientis

Disrupting Neurodegeneration with Cell-Based Precision

HOPE-Neuron Therapeutx is pioneering a non-stem-cell, device-enabled therapy to restore immune balance and deliver real hope for ALS patients and beyond.

Explore Our Mission

/ ABOUT US

Where Science Meets HOPE

HOPE-Neuron Therapeutx is a biotechnology company developing SELane tx™, a novel therapeutic platform designed to treat ALS and related autoimmune neurodegenerative disorders. By harnessing mechanotransduction and controlled hyperoxia, we trigger a natural apoptotic process that reprograms the immune system—without drugs or stem cells.

Backed by published research, leading clinical partnerships, and a growing global IP portfolio, we aim to bring disruptive, scalable healing to patients with ALS, MS, Parkinson’s, and eventually Alzheimer’s.

Explore Our Platform

/ OUR SCIENCE

SELane tx™: Precision Apoptogenics

A cell-based (not stem cell) therapeutic platform engineered to reverse immune dysfunction.

Non-drug, sterile 30-minute IV treatment

Mechanotransduction-enhanced hyperoxia

Stimulates apoptotic cells (ACs) in withdrawn blood

Reinforces efferocytosis – switching M1 "killer"
cells to M2 "healer" cells

How It Works

/ Timeline

Science to HOPE:
A Visual Roadmap

From Discovery to Healing: A Visual Roadmap of Progress

Download Full Timeline PDF

Pre-2022

Discovery Phase

Proof of Concept

2023–2024

2025–2026

Translational Milestones

/ PRECLINICAL RESULTS

Proof of Concept: From Treadmill to Clinic

In preclinical studies, ALS mice treated with SELane tx™ experienced significant improvements in motor function. While untreated mice fell off the treadmill, treated mice "ran, ran, ran" — correlating with a successful M1-to-M2 immune phenotype shift and improved quality of life. These promising results drive our clinical ambitions.

View Data Highlights

Watch the Video

/ FUTURE INDICATIONS

Beyond ALS: A Platform for Neuroimmune Disorders

The mechanism behind SELane tx™ is broadly applicable across neuroinflammatory diseases. Following ALS, we plan to extend validation and IRB trials into:

Multiple Sclerosis (MS)
Alzheimer’s Disease (AD)
Parkinson’s Disease

By rebalancing the immune system through natural apoptotic pathways, we aim to transform the treatment of chronic neurodegeneration.

Explore Clinical Pipeline

/ INVESTORS

Invest in the Future of Immune Reprogramming

A disruptive, device-enabled platform with multi-indication market potential.

IRB-approved ALS trials with Mayo Clinic & Banner Health
Device-based therapy with no drug toxicity
Multi-layered IP across U.S., Japan, Canada, India & more
Global unmet need in ALS, MS, PD, and AD
Revenue potential: $17.9B - $68B over 3-10 years

HOPE-Neuron Therapeutx: Investor Overview

/ TEAM

Mission-Led, Expert-Driven

Full Leadership Team

/ 01

Ronald H. Lane, PhD

Founder & Executive Chairman. Neurobiologist and inventor of the SELane tx™ platform.

/ 02

Shafeeq Ladha, MD

Principal Investigator and Director of the Gregory W. Fulton ALS Clinic at Barrow Neurologic Institute.

/ 03

Yansheng Du, PhD

Professor of Neurology at Indiana University School of Medicine, overseeing pre-clinical transgenic research.

/ 04

Greg Gosch

Start-up CEO with extensive biotech commercialization experience.

/ 05

Mike Kanalsky

Chief Financial Officer, regulatory and registration lead.

/ 06

Mark Forney

Corporate Development and Securities Strategy Consultant.

/ Publications

The Science of Efferocytosis

Explore the peer-reviewed evidence and evolving understanding of how apoptotic cell signals and immune cell transitions (M1 → M2) can reshape the future of neurodegeneration treatment.